3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Interventions
Carboplatin
283
Cisplatin
225
Pemetrexed
196
Paclitaxel
151
Docetaxel
132
pembrolizumab
109
Gemcitabine
94
Etoposide
64
Erlotinib Hydrochloride
59
Radiotherapy
54
Vinorelbine
47
durvalumab
46
Gefitinib
46
Bevacizumab
46
atezolizumab
42
Nivolumab
40
Drug Therapy
34
osimertinib
30
Topotecan
29
tislelizumab
23
130-nm albumin-bound paclitaxel
23
Radiosurgery
21
Ipilimumab
18
Crizotinib
18
Magnetic Resonance Spectroscopy
15
Albumin-Bound Paclitaxel
15
Surgical Procedures, Operative
14
aumolertinib
13
Platinum
13
Injections
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
vadimezan
×
Thoracic
×
Clear all
NCT00662597
2020-12-24
ATRACT-1
Novartis
Phase 3
Terminated
1,285 enrolled
NCT00738387
2020-12-24
ATTRACT-2
Novartis
Phase 3
Terminated
900 enrolled